Trending Now - Planned Parenthood Opposes Hawley's Bill to Revoke Mifepristone Approval

WHO:

Sen. Josh Hawley, R-Mo.

Sarah Taylor-Nanista, executive director of Planned Parenthood Votes Colorado.

Katie Glenn Daniel, SBA Director of Legal Affairs.

Ryan T. Anderson, president of the Ethics and Public Policy Center.

Jamie Bryan Hall, director of data analysis at the Ethics and Public Policy Center.

WHAT:

Sen. Josh Hawley introduced legislation titled the "Safeguarding Women from Chemical Abortion Act" on March 11th, 2026.

The bill aims to revoke the FDA's approval of mifepristone, allow women to sue manufacturers for harm, and classify the labeling and distribution of mifepristone for abortion as violations of the Federal Food, Drug, and Cosmetic Act.

A study reviewed 865,727 prescribed mifepristone abortions from 2017 to 2023, finding that 10.93% of women experienced serious adverse events within 45 days following a mifepristone abortion.

Planned Parenthood officials criticized the bill, stating it is based on false claims about the safety of mifepristone.

WHERE:

Colorado, where Planned Parenthood officials are based.

Washington, D.C., where the Senate Judiciary Committee hearing took place on September 29th, 2021.

WHEN:

The legislation was introduced on March 11th, 2026.

The Senate Judiciary Committee hearing occurred on September 29th, 2021.

The study reviewed data from 2017 to 2023.

WHY:

Hawley stated that "No amount of profit justifies what has happened to these women," indicating a motivation to protect women's health.

Taylor-Nanista argued that the bill is about shutting down abortion access, particularly medication abortion, at a time when millions rely on it.

HOW:

The bill would revoke FDA approval of mifepristone and allow legal action against manufacturers by women claiming harm from chemical abortions.

(UPDATED March 14, 2026 01:26 UTC)

Senator Josh Hawley introduced the "Safeguarding Women from Chemical Abortion Act" on March 11, aiming to revoke the FDA's approval of mifepristone and allow women to sue manufacturers for harm. A study of over 865,000 mifepristone abortions found that nearly eleven percent of women experienced serious adverse events within 45 days, prompting criticism from Planned Parenthood officials who argue the bill is based on false claims about the drug's safety. Hawley emphasized the need to protect women's health, while Planned Parenthood's Sarah Taylor-Nanista contended that the legislation seeks to restrict access to medication abortion for millions who depend on it.